GLP 1 Tirzepatide
Provider evaluation · Appropriate testing · Ongoing monitoring
Tirzepatide Works On Two Receptors, Not One
Tirzepatide is the active ingredient in Mounjaro and Zepbound. Unlike semaglutide, which acts on the GLP-1 receptor, tirzepatide acts on both GLP-1 and GIP. GIP is a second incretin hormone involved in insulin response and fat metabolism, and adding it changes how the medication behaves. In the SURMOUNT-5 trial, the first direct head-to-head comparison of the two medications, tirzepatide produced greater weight reduction than semaglutide over 72 weeks, along with greater improvements in blood pressure, HbA1c, fasting insulin, triglycerides, and HDL cholesterol. Body composition data also suggests tirzepatide loses a smaller proportion of lean mass than semaglutide, though both require the same protein and resistance training approach. Superior on average is not the same as right for you. Tolerance, your other prescriptions, your medical history, and what you can actually stay on determine which medication fits. That decision is made at our Naples, Fort Myers, or Coral Springs clinic with a provider who has your labs in front of them. Results vary by individual.
Two Receptors, One Clinical Relationship
Tirzepatide at T Clinics USA runs inside a program built around body composition and metabolic markers, at three Florida clinics.
How It Works
